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The RPS6KB1 gene is amplified and overexpressed in approximately 10% of breast carcinomas and has been found associated with
poor prognosis. We studied the prognostic significance of P70 S6 kinase protein (PS6K) overexpression in a series of 452 node-
negative premenopausal early-stage breast cancer patients (median follow-up: 10.8 years). Immunohistochemistry was used to assess
PS6K expression in the primary tumour, which had previously been analysed for a panel of established prognostic factors in breast
cancer. In a univariate analysis, PS6K overexpression was associated with worse distant disease-free survival as well as impaired
locoregional control (HR 1.80, P 0.025 and HR 2.50, P 0.006, respectively). In a multivariate analysis including other prognostic factors,
PS6K overexpression remained an independent predictor for poor locoregional control (RR 2.67, P 0.003). To our knowledge, P70
S6 kinase protein is the first oncogenic marker that has prognostic impact on locoregional control and therefore may have clinical
implications in determining the local treatment strategy in early-stage breast cancer patients.
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The treatment of breast cancer is guided by risk factors.
Approximately 70% of all node-negative breast cancer patients
can be cured by locoregional therapy alone. This automatically
implies that the remaining 30% of these patients will develop a
recurrence despite adequate locoregional therapy. Currently,
treatment strategy in breast cancer is based upon tumour stage,
grade, and hormone receptor status. Additional prognostic factors
are greatly needed, first to select those patients who might benefit
from adjuvant systemic therapy and second to optimise locor-
egional therapy in order to avoid locoregional recurrences.
The prognostic significance of a considerable number of tumour
markers has already been investigated but to date, none of these
factors can be used to guide the treatment of primary breast
cancer.
A recent study by Barlund et al (2000a) demonstrated that
amplification of a putative tumour marker called P70 S6 kinase
protein (PS6K) might be associated with poor outcome in breast
cancer. In addition, the authors reported that RPS6KB1 gene
amplification and PS6K overexpression are significantly corre-
lated.
The RPS6KB1 gene is located at 17q23 and amplified in
approximately 10% of all primary breast cancer cases. PS6K is a
ribosomal protein that is involved in the progression from the G1
to Sphase of the cell cycle. It is rapidly activated in response to
mitogenic stimuli, for example, growth factors, cytokines, and
oncogene products (Grove et al, 1991; Lane et al, 1993; Chou et al,
1995; Grammer et al, 1996; Thomas et al, 1997; Couch et al, 1999;
Barlund et al, 2000b; Wu et al, 2000; Latham et al, 2001; Monni
et al, 2001; Andersen et al, 2002; Li et al, 2002; Sinclair et al, 2002;
Sinclair et al, 2003).
To study the significance of P70 S6 kinase protein compared
with other established prognostic factors in breast cancer, we have
tested the prognostic significance of PS6K overexpression in a
subset of node-negative premenopausal early breast cancer
patients. In this series, we have shown previously that premeno-
pausal node-negative breast cancer patients whose tumours show
p53 accumulation have a poor response to one cycle of adjuvant
chemotherapy, whereas patients whose tumours have no accumu-
lation of p53 benefit from adjuvant chemotherapy. In addition, we
showed Ki-67 overexpression, negative ER status, and young age
(o43 years) to be associated with worse prognosis (Clahsen et al,
1998).
PATIENTS AND METHODS
Patients
All patients were drawn from EORTC trial 10854 (1986–1991,
median follow up 10.8 years). This trial, which randomised 2795
patients, studied whether one course of peri-operative chemother-
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yapy given directly after surgery yields better results in terms of
treatment outcome than surgery alone. Peri-operative chemother-
apy consisted of one single course of doxorubicin 50mgm
 2,5 -
fluorouracil 600mgm
 2, and cyclophosphamide 600mgm
 2
(FAC), administered intravenously within 36h after surgery.
Axillary lymph node-positive premenopausal patients in the
peri-operative chemotherapy group were recommended to receive
five additional cycles of cyclophosphamide, methotrexate, and 5-
fluorouracil (CMF) postoperatively. Node-positive patients, young-
er than 50 years, who did not receive peri-operative chemotherapy,
were advised to be treated with one conventional course of FAC
followed by five cycles of CMF after surgery. At randomisation,
patients were stratified for institution, age (p50 years or 450
years), and surgical procedure (breast conserving therapy and
modified radical mastectomy). Prolonged adjuvant systemic
treatment was left to the discretion of the local investigator (van
der Hage et al, 2001).
In total, 676 node-negative premenopausal patients were
enrolled in this trial and representative tumour material was
collected for 452 patients. Tumour material consisted of formalin-
fixed, paraffin-embedded tumour blocks. Tumours were histolo-
gically typed and graded (Elston et al, 1991) centrally by one
pathologist; immunohistochemistry to assess the expression of
various proteins has been performed. Results of these studies have
been reported previously (Clahsen et al, 1998). For the present
study, assays were reviewed simultaneously by two investigators
(MJ Van de Vijver, JA Van der Hage) who had to come to an
agreement in case of any uncertainties. During the evaluation of
the results, the investigators were blinded for the clinical outcome
of the patients.
p70 S6 kinase protein expression
A standard indirect immunoperoxidase protocol with a 3,30-
diaminobenzidine/imidazole solution as a chromogen was used.
Before incubation with the primary antibody, antigen retrieval was
done by boiling the sections in 10mM citrate buffer for 10min
using a microwave oven. PS6K expression was determined using a
polyclonal anti-p70 s6k antibody (sc-230 Santa Cruz Biotechnol-
ogy, Santa Cruz, USA) (1:1000 dilution in PBS containing 1%
bovine serum albumin). PS6K staining was evaluated in tumour
cells and in normal ductal epithelial cells. PS6K staining was scored
categorical as: 0¼no staining; 1¼weak cytoplasmic staining;
2¼moderate cytoplasmic staining; 3¼strong cytoplasmic stain-
ing. In all cases analysed, the staining was homogeneously
distributed in the normal cells and also in the tumour cells. If
the difference in staining score between the tumour cells and the
normal epithelial ducts was greater or equal than two, tumours
were deemed PS6K positive.
RPS6KB1 gene amplification
Two-colour FISH of tumor interphase nuclei was performed
according to the ERBB2 short protocol of Ventana Medical
Systems, Inc. (Tucson, AZ, USA). The Spectrum Orange-labelled
chromosome 17 centromeric probe was purchased from Vysis, Inc.
(Downers Grove, IL, USA), the unlabelled bacterial artificial
chromosome (BAC) clones for PS6K was isolated from a BAC
library (RPCI-13 BAC library, Research Genetics, Inc.). Fluorescent
signals were counted in 2 20 non-overlapping nuclei per
component. Mapping of the PS6K BAC was verified by FISH on
metaphase chromosomes.
Other tumour markers
Previously, tumour sections had been stained and analysed for
oestrogen and progesterone receptor status, Ki-67 positivity, P53
expression, HER2 expression, and mitotic index (Clahsen et al,
1998).
Statistical methods
This analysis was based on locoregional control, distant-disease
free survival, and overall survival. Locoregional recurrence was
defined as the time to locoregional recurrence as a first event.
Locoregional recurrences occurring simultaneously or after the
diagnosis of distant metastasis or contralateral breast cancer or a
secondary primary tumour were censored. Distant disease-free
survival was defined as the time to distant metastasis or death,
whichever of the events happened first. All variables were first
analysed for their prognostic importance in a univariate analysis.
Table 1 Patient characteristics
N¼452
Age (year)
Median (range) 44 (24–63)
Local treatment (N (%))
Breast-conserving therapy 368 (81)
Mastectomy 84 (19)
Tumour diameter (N (%))
p2cm 278 (62)
42cm 148 (33)
Unknown 26 (6)
Histologic tumour type (N (%))
Infiltrating ductal 316 (70)
Infiltrating lobular 34 (8)
Other 91 (20)
Unknown 11 (2)
Histologic tumour grade (N (%))
I 155 (34)
II 144 (32)
III 131 (21)
Unknown 22 (5)
ER status (N (%))
Positive 390 (86)
Negative 46 (10)
Unknown 16 (4)
PgR status (N (%))
Positive 329 (73)
Negative 106 (23)
Unknown 17 (4)
HER2 overexpression (N (%))
Negative 380 (84)
Positive 60 (13)
Unknown 12 (3)
p53 expression (N (%))
Negative 359 (79)
Positive 81 (18)
Unknown 12 (3)
Ki-67 (N (%))
Negative 217 (48)
Positive 215 (48)
Unknown 20 (4)
PS6K
Negative 391 (87)
Positive 39 (9)
Unknown 22 (5)
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(negative vs positive), ER status (negative vs positive), PgR status
(negative vs positive), HER2 overexpression (negative vs positive),
Ki67 (negative, i.e. p20% of positive tumour cells, vs positive,
420% positive tumour cells), histologic tumour grade (grade I vs
grade II vs grade III), tumour diameter (Tp2cmvs T42cm), and
p53 (negative vs positive).
To test the independent prognostic significance of PS6K
overexpression, we included PS6K together with the previously
tested markers into a multivariate Cox regression analysis for
overall survival, progression-free survival, distant disease-free
survival, and locoregional control. Only markers that were
significant predictors in the univariate analysis were included in
the multivariate analysis.
A Cox proportional hazards model was used for the univariate
and multivariate analyses (Cox, 1972). For factors with only two
levels the second one was compared to the first one, while for
factors with more than two levels dummy variables were used to
compare each level to the first one. Patients who had missing
information for any of the variables in the analysis were excluded
when this variable was included in the model. All tests were two-
sided with a 5% alpha level.
RESULTS
Patient characteristics are listed in Table 1. At the time of the
analysis, the median follow-up period was 10.8 years, 80 (18%) of
Table 2 Event rates
Number of events
Patient characteristics N¼452 Overall survival Locoregional recurrence (first event) Distant disease-free survival
Local treatment (N (%))
Breast-conserving therapy 368 (81) 65 (18) 58 (16) 102 (28)
Mastectomy 84 (19) 15 (18) 9 (11) 24 (29)
Tumour diameter (N (%))
p2cm 278 (62) 34 (12) 41 (15) 68 (24)
42cm 148 (33) 40 (27) 21 (14) 51 (34)
Unknown 26 (6) 6 (23) 5 (19) 7 (27)
Histologic tumour type (N (%))
Infiltrating ductal 316 (70) 60 (19) 48 (15) 91 (29)
Infiltrating lobular 34 (8) 4 (12) 9 (26) 7 (21)
Other 91 (20) 14 (15) 8 (9) 25 (27)
Unknown 11 (2) 2 (18) 2 (18) 3 (27)
Histologic tumour grade (N (%))
I 155 (34) 10 (6) 23 (15) 30 (19)
II 144 (32) 30 (21) 27 (19) 45 (31)
III 131 (21) 36 (27) 14 (11) 47 (36)
Unknown 22 (5) 4 (18) 3 (14) 4 (18)
ER status (N (%))
Positive 390 (86) 64 (16) 60 (15) 104 (27)
Negative 46 (10) 13 (28) 4 (9) 18 (39)
Unknown 16 (4) 3 (19) 3 (19) 4 (25)
PgR status (N (%))
Positive 329 (73) 5 (16) 53 (16) 90 (27)
Negative 106 (23) 27 (25) 12 (11) 33 (31)
Unknown 17 (4) 2 (12) 2 (12) 3 (18)
HER2 overexpression (N (%))
Negative 380 (84) 66 (17) 52 (14) 107 (28)
Positive 60 (13) 12 (20) 13 (22) 16 (27)
Unknown 12 (3) 2 (17) 2 (17) 3 (25)
P53 expression (N (%))
Negative 359 (79) 59 (16) 47 (13) 99 (28)
Positive 81 (18) 19 (23) 18 (22) 24 (30)
Unknown 12 (3) 2 (17) 2 (17) 3 (25)
Ki-67 (N (%))
Negative 217 (48) 19 (9) 36 (17) 43 (20)
Positive 215 (48) 59 (27) 27 (13) 78 (36)
Unknown 20 (4) 2 (10) 4 (20) 5 (25)
PS6K
Negative 391 (87) 66 (17) 52 (13) 102 (26)
Positive 39 (9) 8 (21) 11 (28) 17 (44)
Unknown 22 (5) 6 (27) 4 (18) 7 (32)
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distant metastases or death, and 67 (15%) patients experienced a
locoregional recurrence as first event (see Table 2). PS6K
expression levels could be assessed in 430 tumours. In all, 39
tumours (9%) showed PS6K overexpression (Table 1). Examples of
PS6K overexpression are shown in Figure 1A & B.
Univariate analyses
In the univariate analyses, we could not confirm a significant
association between PS6K overexpression and overall survival
(Table 3). However, PS6K overexpression was a significant
predictor for increased risk of locoregional recurrence (HR 2.50,
95% CI 1.30–4.81, P¼0.006) and of developing distant metastases
(HR 1.80, 95% CI 1.08–3.01, P¼0.025).
Multivariate analyses
Apart from PS6K, p53 was the only significant risk factor for
locoregional recurrence in the univariate analysis. When including
these two factors in a multivariate model, PS6K appears as the only
independent prognostic factor for locoregional control predicting
a poor control rate in PS6K overexpressing cases (HR 2.67, 95% CI
1.39–5.14, P¼0.003, Table 4).
Variables significantly associated with distant disease-free
survival in the univariate analysis were PS6K, ER status,
Ki67, grade, and tumour diameter. In a multivariate model
including all these factors, Ki-67 overexpression was the only
independent prognostic factor associated with poor distant
disease-free survival (HR 1.79, 95% CI 1.11–2.91, P¼0.018,
Table 4). PS6K as a prognostic factor did not remain
significant in the multivariate analysis. In addition, Ki-67
Figure 1 (A & B) Two cases of PS6K overexpressing breast cancer tumours.
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overall survival.
PS6K overexpression in patients who underwent breast-
conserving treatment
In all, 368 patients underwent breast-conserving therapy. Event
rates are shown in Table 5. The prognostic impact of PS6K was
similar to that of the overall population. PS6K remained a
predictor of poor locoregional control (HR 2.83, 95% CI 1.42–
5.62, P¼0.003) but not for overall survival (HR1.44, 95 CI 0.66–
3.18, P¼0.36) (Table 6). In the multivariate analyses, Ki67
remained an independent predictor for distant disease (RR 1.78,
95% CI 1.03–3.07, P¼0.038). Tumour grade remained an
independent prognostic factor for poor survival (RR 1.63, 95%
CI 1.04–2.53, P¼0.032) (Table 7).
FISH
A tissue microarray (TMA) was constructed from 12 tumours that
showed PS6K overexpression, as assessed by immunohistochem-
istry. Amplification was studied using FISH by hybridising the
TMA to a PS6K BAC probe and a CEP17 chromosome 17
centromeric probe. Probe signals and CEP17 signals were counted
in each nucleus and a ratio of mean probe signal to mean CEP17
signal was calculated. Ratios of X2 were scored as amplification.
Eight of the 12 tumours with PS6K overexpression (75%) showed
PS6K gene amplification, which is in accordance with the data
shown by Barlund et al (2000a).
Correlation between HER2 and PS6K
As the PS6K gene and the HER2 gene are both located on
chromosome 17, and amplification has been reported to occur in
both genes simultaneously, we studied the correlation of PS6K
expression and HER2 expression and between PS6K expression
and Ki67 expression, respectively. Based on available data, we
found a significant association between PS6K and HER2 expres-
sion (Fisher’s exact test (two sided) P¼0.01), whereas no
significant association was found between PS6K positivity and
Ki67 positivity (Fisher’s exact test (two sided) P¼0.24).
DISCUSSION
We have found that P70 S6 kinase protein overexpression in breast
cancer is associated with increased risk of locoregional recurrence.
To our knowledge, no other oncogenic markers as predictors of
locoregional recurrence have been identified previously. At
present, the common risk factors for local control after breast-
conserving treatment are: patient age, margin status, and the
presence of an extensive intraductal component (De la Rochefor-
diere et al, 1993; Elkhuizen et al, 1998; Voogd et al, 1999, 2001).
The addition of new predictive markers for locoregional recur-
rence may help in guiding the optimal type of local therapy. This is
of particular importance since local therapy does not only have an
impact on locoregional control but also on survival (Shukla et al,
1999; Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG), 2000).
P70 S6 kinase protein overexpression was associated with an
increased risk of locoregional recurrence when all patients were
analysed. The majority of the patients (N¼368) underwent breast-
conserving treatment. When these patients were analysed sepa-
rately. PS6K remained an independent predictor of locoregional
recurrence. In the univariate analysis, p53 overexpression was also
associated with an increased risk of locoregional recurrence (HR
1.85, P¼0.027); however, this was not the case for the subset of
patients who underwent breast-conserving therapy (data not
shown). In addition, 5-year follow-up results concerning the
impact of P53 and PS6K status on locoregional control
Table 3 Univariate analyses all patients (N¼430)
Locoregional control Distant disease-free survival Overall survival
Marker Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
PS6K+ 2.50 1.30–4.81 0.006 1.80 1.08–3.01 0.025 1.27 0.61–2.64 0.526
ER+ 1.38 0.50–3.79 0.536 0.54 0.33–0.90 0.017 0.50 0.27–0.90 0.021
PgR+ 1.31 0.70–2.45 0.403 0.81 0.54–1.20 0.287 0.55 0.35–0.88 0.013
HER2+ 1.64 0.89–3.01 0.111 0.84 0.56–1.60 0.95 1.17 0.63–2.17 0.617
Ki 67+ 0.96 0.58–1.58 0.856 2.24 1.54–3.25 o0.0001 3.74 2.22–6.27 o0.0001
Grade
I vs I 1.42 0.81–2.48 0.216 1.75 1.10–2.77 0.018 3.46 1.70–7.08 0.0007
II vs I 0.93 0.48–1.80 0.820 2.28 1.41–3.60 0.0004 5.09 2.53–10.26 o0.0001
Diameter
r42cm 1.13 0.68–1.91 0.651 1.61 1.12–2.31 0.011 2.43 1.54–3.85 0.0001
p53+ 1.85 1.07–3.18 0.027 1.07 0.69–1.67 0.763 1.47 0.87–2.46 0.148
Table 4 Multivariate analyses all patients (N¼430)
Locoregional recurrence
Marker Hazard ratio 95% CI P-value
PS6K+ 2.67 1.39–5.14 0.003
p53 positivity 1.67 0.95–2.96 0.076
Marker Risk ratio 95% CI P-value
Distant disease-free survival
PS6K+ 1.52 0.87–2.64 0.139
ER+ 0.93 0.50–2.91 0.810
Ki67 (X20%) 1.79 1.11–2.91 0.018
Grade III vs I/II 1.07 0.78–1.45 0.689
Diameter 42cm 1.29 0.86–1.94 0.221
Overall survival
ER+ 1.17 0.56–2.43 0.685
PgR+ 1.01 0.57–1.80 0.972
Ki67 (X20%) 2.84 1.44–5.59 0.003
Grade III vs I/II 1.33 0.88–2.00 0.174
Diameter 42cm 1.63 0.99–2.69 0.055
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Number of events
Patient characteristics N¼368 Overall survival Locoregional recurrence (first event) Distant disease-free survival
Tumour diameter (N (%))
Z2cm 249 (68) 32 (13) 38 (15) 59 (24)
42cm 100 (27) 27 (27) 15 (15) 36 (36)
Unknown 19 (5) 6 (32) 5 (26) 7 (37)
Histologic tumour type (N (%))
Infiltrating ductal 260 (71) 48 (18) 41 (16) 73 (28)
Infiltrating lobular 22 (6) 2 (9) 7 (32) 3 (14)
Other 79 (21) 13 (16) 8 (10) 23 (29)
Unknown 7 (2) 2 (29) 2 (29) 3 (43)
Histologic tumour grade (N (%))
I 124 (34) 6 (2) 19 (15) 21 (17)
II 121 (33) 26 (21) 25 (21) 40 (33)
III 107 (29) 30 (28) 11 (10) 37 (35)
Unknown 16 (4) 3 (19) 3 (19) 4 (25)
ER status (N (%))
Positive 319 (87) 52 (16) 51 (16) 85 (27)
Negative 38 (10) 10 (26) 4 (11) 13 (34)
Unknown 11 (3) 3 (27) 3 (27) 4 (37)
PgR status (N (%))
Positive 268 (73) 45 (17) 45 (17) 77 (29)
Negative 87 (24) 18 (21) 11 (13) 22 (25)
Unknown 13 (4) 2 (15) 2 (15) 3 (23)
HER2 overexpression (N (%))
Negative 312 (85) 54 (17) 44 (14) 87 (28)
Positive 48 (13) 9 (19) 12 (25) 12 (25)
Unknown 8 (2) 2 (25) 2 (25) 3 (38)
p53 expression (N (%))
Negative 290 (79) 47 (16) 42 (14) 77 (27)
Positive 70 (19) 16 (23) 14 (20) 22 (31)
Unknown 8 (2) 2 (25) 2 (25) 3 (38)
Ki-67 (N (%))
Negative 175 (48) 16 (9) 32 (18) 33 (19)
Positive 181 (49) 47 (26) 23 (13) 65 (36)
Unknown 12 (3) 2 (17) 3 (25) 4 (33)
PS6K
Negative 322 (88) 54 (17) 45 (14) 83 (26)
Positive 30 (8) 7 (23) 10 (33) 13 (43)
Unknown 16 (4) 4 (25) 3 (19) 6 (38)
Table 6 Univariate analyses (Pts who received breast-conserving therapy n¼368)
Locoregional control Distant disease-free survival Overall survival
Marker Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
PS6K+ 2.83 1.42–5.62 0.003 1.80 1.00–3.23 0.049 1.44 0.66–3.18 0.360
ER+ 1.22 0.44–3.38 0.701 0.65 0.36–1.16 0.146 0.54 0.27–1.06 0.071
PgR+ 1.28 0.66–2.48 0.461 1.09 0.68–1.75 0.728 0.77 0.45–133 0.346
HER2+ 1.79 0.94–3.39 0.075 0.86 0.47–1.57 0.617 1.07 0.53–2.16 0.862
Ki 67+ 0.86 0.50–1.47 0.582 2.31 1.52–3.52 o0.0001 3.40 1.93–6.02 o0.0001
Grade
I vs I 1.58 0.87–2.86 0.136 2.18 1.29–3.70 0.004 4.94 2.03–12.01 0.0004
II vs II 0.86 0.41–1.80 0.683 2.52 1.47–4.30 0.0007 7.12 2.96–17.11 o0.0001
Diameter
R42cm 1.14 0.63–2.07 0.670 1.72 1.14–2.60 0.011 2.24 1.34–3.75 0.002
p53+ 1.47 0.81–2.70 0.209 1.20 0.74–1.92 0.460 1.44 0.82–2.54 0.209
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of follow-up are 93% (95% CI 92.3–94.2) in P53 negative vs. 84%
(95% CI 81.7–87.2) in P53-positive patients and 93% (95% CI
91.8–93.7) vs 83.3% (95% CI 79.0–87.5), respectively.
Several studies have examined the relation between P53 over-
expression and local breast tumour recurrence. A case–control
study of 66 women with local breast tumour relapse following
lumpectomy and radiation therapy showed that p53 overexpres-
sion was an independent predictive factor for ipsilateral breast
tumour recurrence (IBTR) (Noguchi et al, 1997). Recent studies
conducted by Turner et al (2000) and Zellars et al (2000)
demonstrated predictive significance of P53 overexpression for
locoregional recurrence in patients who underwent breast-conser-
ving therapy, as well as in patients who underwent mastectomy.
Turner and colleagues showed in a matched case-control study
comprising 47 cases and 47 controls that overexpression of P53
had prognostic significance in respect to IBTR following lumpect-
omy and radiotherapy (P¼0.003). Zellars and co-workers
demonstrated in 1530 mastectomy-treated breast cancer patients
of whom 259 received adjuvant radiotherapy that P53 over-
expression was independently associated with a significantly
increased local failure rate in patients treated with mastectomy,
with (RR 2.5, 95% CI 1.1–5.7) or without (RR 1.7, 95% CI 1.2–2.4)
radiotherapy. Although, in our series, P53 lost its prognostic
significance in the multivariate analysis, a trend still remained,
suggesting worse locoregional recurrence rates in P53-overexpres-
sing tumours (RR 1.67, 95% CI 0.95–2.96).
Barlund et al (2000a) analysed RPS6KB1 amplification using
FISH in 668 informative primary breast tumours. In all, 9% of the
tumours showed amplification of the RPS6KB1 gene. In their
series, PS6K was significantly associated with poor survival
(P¼0.0021). In addition, the authors analysed overexpression in
a subset of 445 primary breast tumours. P70 S6 kinase protein
staining of cytoplasm was subjectively scored into four groups:
negative (no staining), weak, moderate, or strong staining. For
statistical analyses, the data were combined into two groups: low
expression (negative or weak staining) and high expression
(moderate or strong staining). High expression was seen in
15.6%. There was a statistically significant association between
RPS6KB1 amplification and high P70 S6 kinase protein expression
(P¼0.0004), with 41% of the amplified tumours (FISH) exhibiting
high PS6K expression, and overexpression of PS6K was associated
with poor survival (P¼0.0083) as well. Our results suggest an even
stronger association between amplification and expression, albeit
with not enough data to make a sound statistical comparison.
Moreover, the authors found that patients showing both PS6K and
HER2 amplification had a significant worse prognosis in terms of
breast cancer-specific survival than those with no amplification or
amplification of only one of the genes.
These results together with our data suggest that P70 S6 kinase
protein overexpression may be an important predictor of not only
worse survival but also of poor locoregional control.
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